Dassault Systèmes has united its life sciences and healthcare capabilities into a single AI-native platform, 3D UNIV+RSES, connecting scientific discovery, clinical development, manufacturing and real-world patient outcomes in one continuous cycle, the company announced on October 28, 2026. The platform brings together its BIOVIA, MEDIDATA and newly acquired ArisGlobal brands, and it is led by a new sector chief executive, Dr Ashwini Zenooz, formerly of the US Department of Veterans Affairs and Salesforce. Dassault says the move is designed to help drugmakers learn faster across the whole therapeutic lifecycle, rather than in separate silos.
One Platform From Discovery To Patient
“Life Sciences is reaching its own inflection point,” Dassault chief executive Pascal Daloz said in the announcement. “For years, discovery, clinical development, manufacturing and patient outcomes have been separate worlds, each learning too slowly from the others. Today, we take a decisive step to change that.” Under the new structure, scientific models become smarter as clinical and manufacturing data flow back into them, clinical trials become more informed by discovery work, manufacturing becomes more adaptive, and patient outcomes continuously improve future innovation, the company says.
The platform combines AI with science, Virtual Twins and deep expertise in 3D UNIV+RSES, Dassault’s framework for virtual worlds that model real systems. In practice, that means a drug candidate’s laboratory behaviour, its performance in trials, its production process and its effects in patients can be examined as connected data rather than as four separate handovers. Dassault argues that this context is what turns AI from a tool that summarises documents into a system that produces actionable insight across a product’s life.
The $1.8 Billion ArisGlobal Piece
The unification follows Dassault’s acquisition of ArisGlobal for $1.8 billion in cash at closing, with up to $200 million in additional consideration tied to multi-year AI-related revenue milestones. Reuters reported that the deal closed in September, and Dassault’s October 28 announcement presents the platform as the next step now that the acquisition is complete. ArisGlobal’s AI-native platform serves as a single source of truth for regulatory, safety, quality and medical affairs, serving more than 200 clients, including half of the top 50 global biopharma companies.
ArisGlobal will continue to be led by Aman Wasan as chief executive and will become an integral part of Dassault’s Life Sciences and Healthcare sector alongside BIOVIA and MEDIDATA. BIOVIA pioneered modelling and simulation in science, while MEDIDATA has transformed clinical development across 42,000 trials and 13 million patients, according to Dassault. ArisGlobal adds the regulatory and safety backbone that connects those stages to the real world, where drugs are approved, monitored and updated after launch.
A New Leader For A New Structure
Dr Ashwini Zenooz has been appointed executive vice president and chief executive of the Life Sciences and Healthcare sector, in a newly created role, and will sit on Dassault’s executive committee reporting to Daloz. She will lead MEDIDATA, BIOVIA and ArisGlobal, with responsibility for strategy, integration, go-to-market and sales, as well as strategic partnerships across pharma, biotech, medtech, diagnostics and digital health.
Zenooz brings a background as a physician, technology leader and entrepreneur, with expertise in telehealth, precision medicine, mental health and applied AI, having held leadership roles at Salesforce, Commure and the US Department of Veterans Affairs. She is a fellowship-trained radiologist and maintains an active California medical licence. Her appointment signals that Dassault wants the sector run by someone who has worked on both the clinical and the technology sides of healthcare, rather than by a software executive alone.
Why It Matters
This matters because life sciences AI is shifting from single-task tools to platforms that follow a drug across its entire life. A virtual patient model or a drug-discovery assistant is valuable on its own, as in our report on Atlas Bio’s virtual patients and our report on Claude’s drug-discovery work. But the expensive failures in pharma usually happen at the handovers: a promising molecule that fails in trials, a trial design that manufacturing cannot scale, or a safety signal that arrives too late to change practice. A platform that keeps those stages connected attacks that specific weakness.
It also matters as a competitive signal. Dassault, a company built on engineering simulation, is now positioning itself as an AI platform provider for an industry that spends heavily on software but has been slow to unify it. If 3D UNIV+RSES delivers faster trials and more adaptive manufacturing, rivals that sell point solutions will face pressure to show how their tools connect. If it does not, Dassault will have spent $1.8 billion plus integration effort on a structure that customers experience as three brands with a shared logo.
Background
Dassault Systèmes has built its life sciences position over more than a decade, and in 2020 it unveiled an ambition to extend Virtual Twins from the world of things into the world of life, bringing together biosciences, material sciences and information sciences into complete living virtual models. The company says its 3DEXPERIENCE agentic platform now helps 390,000 customers across industries collaborate and create sustainable innovations.
Source: Dassault announcement
0 Comments